Don't miss
-
Molecular Analysis for Precision Oncology Congress
Paris, 28-30 October 2023 -
ESMO Congress 2023
Madrid, 20-24 October 2023
From ESMO Breast Congress 2023
Early-phase data from targeting HER3 with ADC are encouraging
Some studies presented suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative disease and triple-negative breast cancer
Extended safety information and PROs data support key trial results in metastatic breast cancer
Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant in this setting, despite moderate drop-out rates for PROs
In the Spotlight
Gathering preclinical pace: cellular immunotherapy against solid tumours
Two recently published studies provide preclinical insights into ‘training’ CAR T cells that may potentially lead to more effective and less toxic immunotherapy approaches
HPV vaccination uptake reflects our efforts as one oncology community
Cervical cancer is a preventable disease so, although research advances are increasing treatment opportunities for all women diagnosed at any stage, we must stop it before it hits.
David Crosby